Patent · US Active

Prefusion RSV F proteins and their use

US10858400B2 · kind B2 · utility

0Cited by
0References
19Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 26, 2017
Grant dateDec 8, 2020
Priority date
Expiry dateNov 12, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2760/18534
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.